Orexo AB (ORXOF)
OTHER OTC:ORXOF
Want to see ORXOF full AI Analyst Report?
ORXOF Stock Chart & Stats
$3.82
-$0.42(-28.00%)
At close: 4:00 PM EDT
$3.82
-$0.42(-28.00%)
Day’s Range― - ―
52-Week Range$1.08 - $4.09
Previous CloseN/A
Volume3.00K
Average Volume (3M)66.00
Market Cap
$70.98M
Enterprise Value$244.39M
Total Cash (Recent Filing)$912.40M
Total Debt (Recent Filing)$492.20M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Jul 22, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding35,127,056
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap3.44
Enterprise Value/Revenue0.91
Enterprise Value/Gross Profit-1.57
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.36M
Bulls Say, Bears Say
Bulls Say
Stronger Liquidity / Net CashThe ZUBSOLV U.S. sale converted a material asset into cash, producing a reported net cash position and management's stated two-year runway. This materially reduces near-term refinancing pressure, gives flexibility to fund R&D milestones and partner deals, and improves financial resilience over coming quarters.
Clear R&D Milestone RoadmapManagement provided concrete timing for three core programs, which creates a sequenced development plan and measurable near-term value drivers. A defined timeline helps prioritize capital, attract partners or funders, and allows investors to assess execution against specific clinical and regulatory milestones over the next 6–12 months.
Early Non-dilutive Program FundingEmerging BARDA and partner funding reduces Orexo's net burn on prioritized programs, lowering the cash required to advance clinical work. Reliable external funding for specific programs is a durable structural benefit that de-risks execution and stretches the company's cash runway without immediate equity dilution.
Bears Say
Very Weak Post-divestment Revenue BaseWith core commercial revenues largely divested, the remaining business generates almost no recurring product revenue. That thin revenue base cannot sustainably fund operations or R&D, increasing reliance on transaction proceeds, partnerships, or grants and raising execution risk if external funding slows or milestones slip.
Volatile Leverage And Uneven Equity QualityHistorical swings from negative equity to net cash reflect a volatile capital structure. That instability limits long-term financial flexibility, increases refinancing and covenant risk, and makes sustaining multi-year R&D investments precarious without consistent external funding or recurring revenue growth.
Unresolved Legal And Near-term Refinancing RiskAn open DOJ probe and an expected bond covenant breach create structural downside: legal costs, reputational impact, and forced bond redemption or refinancing could rapidly deplete cash or require distress financing. These risks can alter strategy, delay programs, or force dilutive/asset-sale outcomes.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.08 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $70.98M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 22, 2026 which is in 82 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -$0.322 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.322.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.17.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.322 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Ownership Overview
―
Insiders
0.13% Mutual Funds
― Other Institutional Investors
99.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---